What the changes say
- Rigel expanded commercial operations with REZLIDHIA for R/R AML and settled Annora generic litigation for TAVALISSE.
- The company faced increased scrutiny on pricing methodologies and drug rebate reporting compliance.
- Regulatory hurdles grew with new EU health technology assessment regulations and UK orphan drug rules.
What changed since the prior 10-K
New
- NewRisks Related to Our Business and Our Industry
development for a number of reasons. For example, potential product candidates may, on later stage clinical trial, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products
Our product candidates or acquired drugs like REZLIDHIA for AML may fail in clinical trials due to inadequate efficacy or harmful side effects.
- NewRisks Related to Our Business and Our Industry
to period, and our actual results may differ significantly from our estimated allowances for discounts and rebates. Changes in estimates and assumptions may have an adverse effect on our business, results of operations and financial condition
Government bodies have increased scrutiny on our drug pricing calculations under the Medicaid Drug Rebate Program, risking False Claims Act allegations.
- NewRisks Related to Our Business and Our Industry
Our recent operating income may not be sustainable, and we may continue to incur significant losses
Despite recognizing operating income in 2024 and 2025, we may not sustain profitability if our product sales and collaboration revenues decline.
- NewRisks Related to Our Business and Our Industry
our collaborations, our ability to receive patent protection or protect our proprietary information may otherwise be impaired. In addition, some of the technology we have licensed relies on patented inventions developed using US government resources
Certain in-licensed technologies rely on US government resources, giving the government rights that could impair our patent protection and business operations.
- NewRisks Related to Our Business and Our Industry
partners, might not be able to compete successfully with competitors’ existing or future products or obtain regulatory approval in the US or elsewhere
We face intense competition from pharmaceutical and biotech competitors in securing collaborative arrangements, licensing technologies, and gaining regulatory approvals.
- NewRisks Related to Our Business and Our Industry
orphan conditions in the UK will no longer be, and conditions that are not currently designated as orphan conditions in the EU will be designated as such in the UK
Proposed EU and UK pharmaceutical legislation changes may alter regulatory data protection periods and orphan medicinal product marketing exclusivity.
- NewRisks Related to Our Business and Our Industry
previously useful data. Failure to timely identify and disclose a material cybersecurity incident could result in SEC enforcement actions, litigation, and reputational damage
A cybersecurity incident or failure to timely disclose a breach could result in SEC enforcement actions, litigation, and reputational damage.
- NewRisks Related to Clinical Development and Regulatory Approval
A Fast Track designation by the FDA may not lead to a faster development or regulatory review and does not increase the likelihood that our product candidates will receive approval
An FDA Fast Track designation for our product candidates may not actually lead to faster development, review, or approval.
- NewRisks Related to Commercialization
comparison with its cost. The outcome of HTA assessments is judged on a national basis and some payors may not reimburse the use of our products or may reduce the rate of reimbursement for our products and as a result, revenue from such products may decrease
The EU's new Health Technology Assessment Regulation imposes joint clinical assessments that could negatively impact product pricing and reimbursement.
Dropped
- DroppedRisks Related to Our Business and Our Industry
programs may require additional investment in resources, and could impact availability of previously useful data
- DroppedRisks Related to Our Business and Our Industry
in regulatory review resulting from such disruptions could materially affect the completion of our clinical trials
- DroppedRisks Related to Our Business and Our Industry
our rebate agreement, no federal payments would be available under Medicaid for our covered outpatient drugs or under Medicare Part B for any of our products that may be reimbursed under Part B
- DroppedRisks Related to Our Business and Our Industry
Our success as a company is uncertain due to our history of operating losses and the uncertainty of any future profitability
- DroppedRisks Related to Our Business and Our Industry
We completed a reverse stock split of our shares of common stock, which may reduce and may limit the market trading liquidity of the shares due to the reduced number of shares outstanding and may potentially have an anti-takeover effect
Foreign data protection authorities in Europe scrutinizing international clinical trial programs and research collaborations.
- DroppedRisks Related to Our Business and Our Industry
into consulting arrangements with competing pharmaceutical or biotechnology companies, any of which may have a detrimental impact on our research objectives and could have an adverse effect on our business, financial condition and results of operations
- DroppedRisks Related to Clinical Development and Regulatory Approval
the Center for Medicare Innovation at CMS announced a new model, the Enhancing Oncology Model, that is designed to make high-quality cancer care more affordable to both patients and Medicare
- DroppedRisks Related to Clinical Development and Regulatory Approval
our other clinical programs. If we are unable to enroll the patients in these trials at the projected rate, the completion of the clinical program could be delayed and the costs of conducting the program could increase, either of which could harm our business
- DroppedRisks Related to Commercialization
Bank failures or other events affecting financial institutions could adversely impact our liquidity and other business
Reworded
- 98% rewrittenRisks Related to Our Business and Our Industry
Changes in valuation allowance of deferred tax assets may affect our future operating results
Updated to reflect that in the fourth quarter of 2025, we released the valuation allowance on a significant portion of our federal and state deferred tax assets.
- 89% rewrittenRisks Related to Our Business and Our Industry
Our strategy to expand our hematology and oncology pipeline on our own, or through acquisitions or in-licensing of early or late-stage products or companies, or through partnerships with pharmaceutical and biotechnology companies, as well as academic institutions and government organizations, may not be successful
Expanded to specify our strategy to expand our hematology and oncology pipeline internally and through acquisitions, in-licensing, or partnerships.
- 85% rewrittenRisks Related to Clinical Development and Regulatory Approval
Delays in clinical testing could result in increased costs to us
Removed specific references to the Russian-Ukrainian and Hamas-Israel wars, replacing them broadly with global geopolitical tensions affecting clinical patient enrollment.
- 79% rewrittenRisks Related to Clinical Development and Regulatory Approval
Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability
Adjusted formatting and maintained general risks regarding government authorities and third-party payors limiting medical product prices.
- 76% rewrittenRisks Related to Our Business and Our Industry
Our stock price may be volatile, and our stockholders’ investment in our common stock could decline in value
Standardized bullet formatting for common stock volatility factors without altering the core risk description.
- 69% rewrittenRisks Related to Our Business and Our Industry
The ANDA process can result in generic competition if the patents at issue are not upheld or if the generic competitor is found not to infringe the owner’s patents. If this were to occur with respect to our products or products with which it competes, our business would be harmed
Updated to reflect the March 2025 settlement agreement with Annora resolving patent litigation related to TAVALISSE.
- 66% rewrittenRisks Related to Our Business and Our Industry
Significant changes or developments in US laws or policies, including changes in US healthcare regulation, may have a material adverse effect on our business
Updated to reflect the current administration's commitments to significantly reduce government spending through cuts to federal healthcare programs and workforce reductions at DHHS, FDA, and CMS.
- 63% rewrittenRisks Related to Our Business and Our Industry
We depend on various scientific consultants and advisors for the success and continuation of our research and development efforts
Trimmed the ending description regarding potential competing contracts of scientific advisors.
- 60% rewrittenRisks Related to Our Business and Our Industry
Accordingly, our competitors may succeed in obtaining patent protection, identifying or validating new targets or developing new drug compounds before we do
- 60% rewrittenRisks Related to Our Business and Our Industry
Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts
- 58% rewrittenRisks Related to Our Business and Our Industry
The UK to date has not adopted dedicated AI legislation, instead looking to rely on a principles-based, sector-specific approach to AI regulation
Was: The UK to date has not adopted dedicated AI legislation, instead looking to rely on a principles-based, sector-specific approach to AI regulation. However, in July 2024 it was announced that new AI regulation would in fact be introduced
- 49% rewrittenRisks Related to Our Business and Our Industry
There is a high risk that drug discovery and development efforts might not generate successful product candidates
- 36% rewrittenRisks Related to Our Business and Our Industry
Our success is dependent on intellectual property rights held by us and third parties, and our interest in such rights is complex and uncertain
- 34% rewrittenRisks Related to Our Business and Our Industry
If our corporate collaborations or license agreements are unsuccessful, or if we fail to form new corporate collaborations or license agreements, our research and development efforts could be delayed
- 34% rewrittenRisks Related to Commercialization
Our prospects are highly dependent on our commercial products. To the extent that the commercial success of our products in the US is diminished or is not commercially successful, our business, financial condition and results of operations may be adversely affected, and the price of our common stock may decline
- 33% rewrittenRisks Related to Our Business and Our Industry
Discovery of unforeseen safety problems or increased focus on a known problem could impact our ability to commercialize our products and could result in restrictions on its permissible uses, including withdrawal of the medicine from the market
- 30% rewrittenRisks Related to Our Business and Our Industry
Additional uncertainty may result because no consistent policy regarding the breadth of legal claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims allowed in our or other companies’ patents
- 29% rewrittenRisks Related to Our Business and Our Industry
Our information technology systems, or those used by our CROs or other contractors or consultants, may fail or suffer other breakdowns, cyber-attacks, or information security breaches
- 29% rewrittenRisks Related to Our Business and Our Industry
The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities
Was: The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities
- 26% rewrittenRisks Related to Our Business and Our Industry
Our ability to use net operating losses (NOLs) and certain other tax attributes is uncertain and may be limited
- 24% rewrittenRisks Related to Commercialization
Global economic conditions could adversely impact our business
All 59 risk factors
Headings as the filing states them, in filing order.
Risks Related to Our Business and Our Industry
- 01If the market opportunities for our products and product candidates are smaller than we believe they are, our revenues may be adversely affected, and our business may suffer
- 02We may need to continue to increase the size of our organization and we may encounter difficulties with managing our growth, which could adversely affect our business and results of operations
- 03Our strategy to expand our hematology and oncology pipeline on our own, or through acquisitions or in-licensing of early or late-stage products or companies, or through partnerships with pharmaceutical and biotechnology companies, as well as academic institutions and government organizations, may not be successful89% rewritten
- 04development for a number of reasons. For example, potential product candidates may, on later stage clinical trial, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable productsNew
- 05There is a high risk that drug discovery and development efforts might not generate successful product candidates49% rewritten
- 06The UK to date has not adopted dedicated AI legislation, instead looking to rely on a principles-based, sector-specific approach to AI regulation58% rewritten
- 07Significant changes or developments in US laws or policies, including changes in US healthcare regulation, may have a material adverse effect on our business66% rewritten
- 08The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities29% rewritten
- 09If manufacturers obtain approval for generic versions of our products, or of products with which we compete, our business may be harmed
- 10The ANDA process can result in generic competition if the patents at issue are not upheld or if the generic competitor is found not to infringe the owner’s patents. If this were to occur with respect to our products or products with which it competes, our business would be harmed69% rewritten
- 11Discovery of unforeseen safety problems or increased focus on a known problem could impact our ability to commercialize our products and could result in restrictions on its permissible uses, including withdrawal of the medicine from the market33% rewritten
- 12to period, and our actual results may differ significantly from our estimated allowances for discounts and rebates. Changes in estimates and assumptions may have an adverse effect on our business, results of operations and financial conditionNew
- 13We may need to seek additional capital in the future to sufficiently fund our operations, research and corporate development opportunities
- 14We rely and may continue to rely on two distribution facilities for the sale of our products and potential sale of any of our product candidates
- 15Forecasting potential sales for any of our product candidates will be difficult, and if our projections are inaccurate, our business may be harmed, and our stock price may be adversely affected
- 16We do not and will not have access to all information regarding our products and product candidates we licensed to our collaboration partners
- 17Our future funding requirements will depend on many uncertain factors
- 18Our recent operating income may not be sustainable, and we may continue to incur significant lossesNew
- 19If our corporate collaborations or license agreements are unsuccessful, or if we fail to form new corporate collaborations or license agreements, our research and development efforts could be delayed34% rewritten
- 20If conflicts arise between our collaborators or advisors and us, any of them may act in their self-interest, which may be adverse to our stockholders’ interests
- 21Our success is dependent on intellectual property rights held by us and third parties, and our interest in such rights is complex and uncertain36% rewritten
- 22Additional uncertainty may result because no consistent policy regarding the breadth of legal claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims allowed in our or other companies’ patents30% rewritten
- 23our collaborations, our ability to receive patent protection or protect our proprietary information may otherwise be impaired. In addition, some of the technology we have licensed relies on patented inventions developed using US government resourcesNew
- 24If a dispute arises regarding the infringement or misappropriation of the proprietary rights of others, such dispute could be costly and result in delays in our research and development activities, partnering and commercialization activities
- 25Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts60% rewritten
- 26Our ability to use net operating losses (NOLs) and certain other tax attributes is uncertain and may be limited26% rewritten
- 27Changes in valuation allowance of deferred tax assets may affect our future operating results98% rewritten
- 28Because we expect to be dependent upon collaborative and license agreements, we might not meet our strategic objectives
- 29Securities class action lawsuits or other litigation could result in substantial damages and may divert management’s time and attention from our business
- 30If our competitors develop technologies that are more effective than ours, our commercial opportunity will be reduced or eliminated
- 31Accordingly, our competitors may succeed in obtaining patent protection, identifying or validating new targets or developing new drug compounds before we do60% rewritten
- 32partners, might not be able to compete successfully with competitors’ existing or future products or obtain regulatory approval in the US or elsewhereNew
- 33Our stock price may be volatile, and our stockholders’ investment in our common stock could decline in value76% rewritten
- 34orphan conditions in the UK will no longer be, and conditions that are not currently designated as orphan conditions in the EU will be designated as such in the UKNew
- 35If product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products
- 36We depend on various scientific consultants and advisors for the success and continuation of our research and development efforts63% rewritten
- 37If we use biological and hazardous materials in a manner that causes injury or violates laws, we may be liable for damages, penalties or fines
- 38Our information technology systems, or those used by our CROs or other contractors or consultants, may fail or suffer other breakdowns, cyber-attacks, or information security breaches29% rewritten
- 39previously useful data. Failure to timely identify and disclose a material cybersecurity incident could result in SEC enforcement actions, litigation, and reputational damageNew
- 40Future equity issuances or a sale of a substantial number of shares of our common stock may cause the price of our common stock to decline
Risks Related to Clinical Development and Regulatory Approval
- 41Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability79% rewritten
- 42See “Part I, Item 1 – Business – Government Regulation – Healthcare Reform” of this Annual Report on Form 10-K, for additional information
- 43Delays in clinical testing could result in increased costs to us85% rewritten
- 44A Fast Track designation by the FDA may not lead to a faster development or regulatory review and does not increase the likelihood that our product candidates will receive approvalNew
- 45Negative perception of the efficacy, safety, or tolerability of any investigational medicines that we develop, or of other products similar to products we are developing, could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals
- 46If any of our third-party contractors fail to perform their responsibilities to comply with FDA rules and regulations, the marketing and sales of our products could be delayed and we may be subject to enforcement action, which could decrease our revenues
- 47If we are unable to obtain regulatory approval to market products in the US and foreign jurisdictions, we will not be permitted to commercialize products we or our collaborative partners may develop
Risks Related to Commercialization
- 48Our prospects are highly dependent on our commercial products. To the extent that the commercial success of our products in the US is diminished or is not commercially successful, our business, financial condition and results of operations may be adversely affected, and the price of our common stock may decline34% rewritten
- 49comparison with its cost. The outcome of HTA assessments is judged on a national basis and some payors may not reimburse the use of our products or may reduce the rate of reimbursement for our products and as a result, revenue from such products may decreaseNew
- 50If we are unable to successfully market and distribute our products and retain experienced commercial personnel, our business will be substantially harmed
- 51We may not be able to successfully develop or commercialize our product candidates if problems arise in the clinical testing and approval process
- 52Commercialization of our product candidates depends upon successful completion of extensive preclinical studies and clinical trials to demonstrate their safety and efficacy for humans. Preclinical testing and clinical development are long, expensive and uncertain processes
- 53Global economic conditions could adversely impact our business24% rewritten
- 54Shareholder activism and private securities-related litigation could cause material disruption to our business
- 55Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us, which may be beneficial to our stockholders, more difficult
- 56In addition, Section 203 of the Delaware General Corporation Law (DGCL), which imposes certain restrictions relating to transactions with major stockholders, may discourage, delay or prevent a third party from acquiring us
- 57Increasing use of social media could give rise to liability and may harm our business
- 58Our future success depends on our ability to attract and retain key employees and relationships
- 59Our facilities are located near known earthquake fault zones, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations
Other Rigel Pharmaceuticals 10-Ks
- FY2024 10-K risk factors59 risks
Rigel faces intense pharmaceutical competition, patent challenges for TAVALISSE, and capital dilution risks. The company relies heavily on third-party distributors and collaborative partnerships for pipeline expansion. Strict regulatory compliance, pricing pressures, and future funding needs dominate the operational landscape.
Filed Mar 04, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.